Dianne Finkelstein

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Web-browser encryption of personal health information
    Richard E Morse
    MGH Biostatistics Center, Massachusetts General Hospital, 50 Staniford St, Ste 560, Boston, MA 02114, USA
    BMC Med Inform Decis Mak 11:70. 2011
  2. ncbi Design considerations in a sib-pair study of linkage for susceptibility loci in cancer
    Richard A Kerber
    Population Sciences Program, Hunstman Cancer Institute, Salt Lake City, UT, USA
    BMC Med Genet 9:64. 2008
  3. ncbi Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status
    Steven J Skates
    Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Prev Res (Phila) 4:1401-8. 2011
  4. ncbi A score test for association of a longitudinal marker and an event with missing data
    Dianne M Finkelstein
    Massachusetts General Hospital and Harvard University, Boston, Massachusetts 02114, USA
    Biometrics 66:726-32. 2010
  5. ncbi Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer
    Anthony C Nichols
    Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 16:2138-46. 2010
  6. ncbi Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis
    Kenneth K Tanabe
    Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 2696, USA
    JAMA 299:53-60. 2008
  7. ncbi Predictors of an accurate preoperative sestamibi scan for single-gland parathyroid adenomas
    Antonia E Stephen
    Department of Surgical Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    Arch Surg 142:381-6. 2007
  8. ncbi Quantitatively determined survivin expression levels are of prognostic value in human gliomas
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    J Clin Oncol 20:1063-8. 2002
  9. ncbi Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma
    Philip C Amrein
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 104:1418-27. 2005
  10. ncbi Survival analysis of longitudinal microarrays
    Natasa Rajicic
    Massachusetts General Hospital, Biostatistics Unit 50 Staniford Street, Suite 560, Boston, MA, USA
    Bioinformatics 22:2643-9. 2006

Research Grants

Collaborators

Detail Information

Publications24

  1. ncbi Web-browser encryption of personal health information
    Richard E Morse
    MGH Biostatistics Center, Massachusetts General Hospital, 50 Staniford St, Ste 560, Boston, MA 02114, USA
    BMC Med Inform Decis Mak 11:70. 2011
    ..However it is important to protect patient confidentiality, as many medical conditions are stigmatized and disclosure could result in personal and/or financial loss...
  2. ncbi Design considerations in a sib-pair study of linkage for susceptibility loci in cancer
    Richard A Kerber
    Population Sciences Program, Hunstman Cancer Institute, Salt Lake City, UT, USA
    BMC Med Genet 9:64. 2008
    ..However, the sibpair design is still valuable because it requires few assumptions other than acceptably high penetrance to identify genetic loci...
  3. ncbi Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status
    Steven J Skates
    Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Prev Res (Phila) 4:1401-8. 2011
    ....
  4. ncbi A score test for association of a longitudinal marker and an event with missing data
    Dianne M Finkelstein
    Massachusetts General Hospital and Harvard University, Boston, Massachusetts 02114, USA
    Biometrics 66:726-32. 2010
    ..The problem was motivated by data from an observational study of patients with diabetes...
  5. ncbi Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer
    Anthony C Nichols
    Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 16:2138-46. 2010
    ..To determine whether Bcl2 and HPV together might further characterize treatment response, we examined whether the prognostic value of Bcl2 was independent of HPV status...
  6. ncbi Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis
    Kenneth K Tanabe
    Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 2696, USA
    JAMA 299:53-60. 2008
    ..Overexpression of epidermal growth factor (EGF) in the liver induces transformation to hepatocellular carcinoma in animal models. Polymorphisms in the EGF gene modulate EGF levels...
  7. ncbi Predictors of an accurate preoperative sestamibi scan for single-gland parathyroid adenomas
    Antonia E Stephen
    Department of Surgical Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    Arch Surg 142:381-6. 2007
    ..To investigate why some patients with single parathyroid adenomas have negative preoperative sestamibi scans...
  8. ncbi Quantitatively determined survivin expression levels are of prognostic value in human gliomas
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA
    J Clin Oncol 20:1063-8. 2002
    ..Its expression has been found to be of prognostic significance in several tumor types. This is the first study on the prognostic significance of survivin expression in human gliomas...
  9. ncbi Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma
    Philip C Amrein
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 104:1418-27. 2005
    ....
  10. ncbi Survival analysis of longitudinal microarrays
    Natasa Rajicic
    Massachusetts General Hospital, Biostatistics Unit 50 Staniford Street, Suite 560, Boston, MA, USA
    Bioinformatics 22:2643-9. 2006
    ..gluegrant.org)...
  11. ncbi Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma
    Paul L Nguyen
    Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:1507-13. 2005
    ..9 months. Age less than 60 years and response to WBRT predict post-WBRT survival. Modest rates of late neurotoxicity (15%) were seen and were associated with a total dose greater than 36 Gy...
  12. ncbi Comparing survival of a sample to that of a standard population
    Dianne M Finkelstein
    Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Natl Cancer Inst 95:1434-9. 2003
  13. ncbi Phase II study of paclitaxel and carboplatin for malignant melanoma
    F Stephen Hodi
    Adult Oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Clin Oncol 25:283-6. 2002
    ..Comparisons with other treatment regimens and the search for additional active compounds against melanoma are needed...
  14. ncbi Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter
    Mohamed A Alm El-Din
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 73:69-74. 2009
    ..To evaluate the risk of breast cancer (BC) and the contributing risk factors in women after supradiaphragmatic irradiation (SDI) for Hodgkin's lymphoma (HL)...
  15. ncbi Regression of microalbuminuria in type 1 diabetes
    Bruce A Perkins
    Section on Genetics and Epidemiology, Research Division, Joslin Diabetes Center, Boston, MA 02215, USA
    N Engl J Med 348:2285-93. 2003
    ..Identification of the multiple determinants of the regression of microalbuminuria has implications for current theories about the mechanisms of early diabetic nephropathy...
  16. ncbi Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan
    Edyta Tyminski
    Molecular Neuro-Oncology Laboratories, Neurosurgery Service and Biostatistics Center, Massachusetts General Hospital, Charlestown, Massachusetts, USA
    Cancer Res 65:6850-7. 2005
    ..Therefore, MGH2 provides effective multimodal therapy for gliomas in preclinical models when combined with these chemotherapy agents...
  17. ncbi Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center
    Kristen M Shannon
    Division of Hematology/Oncology, Massachusetts General Hospital, Boston 02114, USA
    Cancer 94:305-13. 2002
    ..The actual number of patients eligible to receive BRCA1/2 genetic testing outweighs the number of patients seen for genetic counseling at the study institution. Finally, limited correlation was found between current predictive models...
  18. ncbi Study of either ifosfamide or teniposide compared to a standard chemotherapy for extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group randomized study (E1588)
    David S Ettinger
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, Room G-88, 1650 Orleans Street, Baltimore, MD, USA
    Lung Cancer 37:311-8. 2002
    ....
  19. ncbi Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes
    Donna K Pauler
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, MP 702, Seattle, WA 98109, USA
    Stat Med 21:3897-911. 2002
    ..Based on these data, predictive schemes for detecting cancer recurrence in new patients based on their longitudinal trajectory are derived...
  20. ncbi Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms
    Daphne W Bell
    Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    Clin Cancer Res 14:4079-84. 2008
    ....
  21. ncbi Prognosis and management of extramammary Paget's disease and the association with secondary malignancies
    Jean Pierre E N Pierie
    Department of Surgery, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands
    J Am Coll Surg 196:45-50. 2003
    ..A thorough search for frequently occurring secondary malignancies might be beneficial to provide the best outcomes for these patients...
  22. ncbi Validity of models for predicting BRCA1 and BRCA2 mutations
    Giovanni Parmigiani
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21205 2011, USA
    Ann Intern Med 147:441-50. 2007
    ..At least 7 models for estimating the probabilities of having a mutation are used widely in clinical and scientific activities; however, the merits and limitations of these models are not fully understood...
  23. ncbi Modelling the relationship between continuous covariates and clinical events using isotonic regression
    Marek Ancukiewicz
    Massachusetts General Hospital, Boston, MA, U.S.A
    Stat Med 22:3151-9. 2003
    ..These methods will be applied to graphically display the risk for an AIDS patient of an opportunistic infection as a function of CD4 count...
  24. ncbi Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
    Cristina R Ferrone
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:2897-902. 2006
    ..CA19-9 levels should be included in a patient's perioperative care and should be considered for prognostic nomograms...

Research Grants12

  1. Methods for Statistical Analysis of Cancer Genetic Network Studies
    Dianne Finkelstein; Fiscal Year: 2007
    ....
  2. COORDINATING CENTER FOR THE CANCER GENETICS NETWORK
    Dianne Finkelstein; Fiscal Year: 2006
    ..We will coordinate our activities with the other members of the Informatics Technology group. ..
  3. Analysis of Longitudinal High Dimensional Data for Burn and Trauma Studies
    Dianne Finkelstein; Fiscal Year: 2007
    ..This knowledge can be used to improve the treatment of severely burned patients resulting in more rapid and complete recovery. ..
  4. STATISTICAL METHODS FOR RESEARCH IN CANCER AND AIDS
    Dianne Finkelstein; Fiscal Year: 2004
    ....
  5. STATISTICAL METHODS FOR RESEARCH IN CANCER AND AIDS
    Dianne Finkelstein; Fiscal Year: 1999
    ....